Fenticonazole nitrate for treatment of vulvovaginitis: Efficacy, safety, and tolerability of 1-gram ovules, administered as ultra-short 2-day regimen

Journal of Chemotherapy

Volumn 16, Issue 2, 2004, Pages 179-186

  Fernandez Alba J ^a,e   Valle Gay, A ^b   Dibildox, M ^c   Vargas, J A ^c   Gonzalez J ^c   Garcia M ^c   Lopez L H ^d  

^a UNIVERSIDAD ANÁHUAC   (Mexico)

^b HOSPITAL GENERAL DE MÉXICO   (Mexico)

^c Depto Invest Clin Altana P   (Mexico)

^d UNIVERSITY OF GUANAJUATO   (Mexico)

^e NONE   (Mexico)

Author keywords

Candida albicans; Eradication; Fenticonazole nitrate; Gardnerella vaginalis; Mixed infections; Symptoms; Trichomonas vaginalis; Vulvovaginitis

Indexed keywords

FENTICONAZOLE NITRATE;

ADOLESCENT; ADULT; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERADICATION THERAPY; FEMALE; GARDNERELLA VAGINALIS; HUMAN; MAJOR CLINICAL STUDY; MICROBIOLOGICAL EXAMINATION; MULTICENTER STUDY; PHASE CONTRAST MICROSCOPY; RECURRENCE RISK; RELAPSE; SHORT COURSE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; VULVOVAGINITIS;

EID: 2942568544     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2004.16.2.179     Document Type: Article

References (39)

1. Sobel JD. Vaginitis. N Engl J Med 1997; 337: 1896-1903.
2. Hay PE. Therapy of bacterial vaginosis. J Antimicrob Chemother 1998; 41(1): 6-9.
3. Haefner HK. Current evaluation and management of vulvovaginitis. Clin Obstet Gynecol 1999; 42(2): 184-195.
4. Pray WS. Treatment of vaginal fungal infections. U S Pharmacist 2001; 26(9): 1-5.
5. Carr PL, Felsenstein D, Friedman RH. Evaluation and management of vaginitis. J Gen Intern Med 1998; 13(5): 335-346.
6. Schaaf VM, Perez-Stable EJ, Borchardt K. The limited value of symptoms and signs in the diagnosis of vaginal infections. Arch Intern Med 1990; 150(9): 1929-1933.
7. Egan ME, Lipsky MS. Diagnosis of vaginitis. Am Fam Physician 2000; 62(5): 1095-1104.
8. Bornstein J, Lakovsky Y, Lavi I, Bar-Am A, Abramovici H. The classic approach to diagnosis of vulvovaginitis: a critical analysis. Infect Dis Obstet Gynecol 2001; 9(2): 105-111.
9. Hill GB. The microbiology of bacterial vaginosis. Am J Obstet Gynecol 1993; 169(2 Pt 2): 450-454.
10. Gonzalez Pedraza AA, Ortiz Zaragoza MC, Irigoyen CA. Bacterial vaginosis a "broad overview". Rev Latinoam Microbiol 1999: 41(1): 25-34.
11. Petrin D, Delgaty K, Bhatt R, Garber G. Clinical and microbiological aspects of Trichomonas vaginalis. Clin Microbiol Rev 1998; 11(2): 300-317.
12. Geiger AM, Foxman B. Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology 1996; 7(2): 182-187.
13. Hurley R, De Louvois J. Candida vaginitis. Postgrad Med J 1979; 55(647): 645-647.
14. Sweet RL. Importance of differential diagnosis in acute vaginitis. Am J Obstet Gynecol 1985; 152 (7 Pt 2): 921-923.
15. Ferris DG, Litaker MS, Woodward L, Mathis D, Hendrich J. Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream. J Fam Pract 1995; 41(5): 443-449.
16. Periti P, Cohen J, Giannotti B, Periti E, Orlandini L. Fenticonazole as antimicrobial chemotherapy of superficial fungal infections. J Chemother 1999; 11 Supp. 3: 3-42.
17. Sobel JD. Treatment of vaginal Candida infections. Expert Opin Pharmacother 2002; 3(8): 1059-1065.
18. Redondo-Lopez V, Meriwether C, Schmitt C, Opitz M, Cook R, Sobel JD. Vulvovaginal candidiasis complicating recurrent bacterial vaginosis. Sex Transm Dis 1990; 17(1): 51-53.
19. Taylor CA, Lipsky MS. Physicians' perceptions of the impact of the reclassification of vaginal antifungal agents. J Fam Pract 1994; 38(2): 157-160.
20. Ferris DG, Nyirjesy P, Sobel JD, Soper D, Pavletic A, Litaker MS. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol 2002; 99(3): 419-425.
21. Nardi D, Cappelletti R, Catto A, Leonardi A, Tajana A, Veronese M. New alpha-aryl-beta,N-imidzolylethyl benzyl and naphthylmethyl ethers with antimycotic and antibacterial activity. Arzneimittelforschung 1981; 31(12): 2123-2126.
22. Veronese M, Salvaterra M, Barzaghi D. Fenticonazole, a new imidazole derivative with antibacterial and antifungal activity. In vitro study. Arzneimittelforschung 1981; 31(12): 2133-2137.
23. Jones BM, Geary I, Lee ME, Duerden BI. Comparison of the in vitro activities of fenticonazole, other imidazoles, metronidazole, and tetracycline against organisms associated with bacterial vaginosis and skin infections. Antimicrob Agents Chemother 1989; 33(6): 970-972.
24. Fontana C, Cammarata E, Greco M, Oliveri S. In vitro activity of fenticonazole on Trichomonas vaginalis and Gardenerella vaginalis. Curr Ther Res 1990; 48: 44-51.
25. Schneider D, Caspi E, Arieli S, Bukovski I. Fenticonazole in the treatment of vaginal candidiasis. Adv Ther 1990; 7: 355-361.
26. Gastaldi A. Treatment of vaginal candidiasis with fenticonazole and miconazol. Curr Ther Res 1985; 38: 489-493.
27. Munoz JR, Villanueva C, Ramos JC, Menendez J, Bailon R, Vargas JA. Eficacia y tolerancia de 200 mg de fenticonazol vs 400 mg de miconazol en el tratamiento intravaginal de la vulvovaginitis micotica. Ginecologia y Obstetricia de Mexico 2002; 70: 59-65.
28. Novelli A, Periti E, Massi GB, Masi R, Mazzei T, Periti P. Systemic absorption of 3H-fenticonazole after vaginal administration of 1 gram in patients. J Chemother 1991; 3(1): 23-27.
29. Bukovski I, Schneider D, Arieli S, Caspi E. Fenticonazole in the treatment of vaginal trichomoniasis and vaginal mixed infections. Adv Ther 1991; 8(4): 166-171.
30. Manth SM, Rindt W, Schnitker J, Weigerding A. Fenticonazole in the treatment of vaginal trichomonas infections. Curr Ther Res 1989; 45(6): 1060-1066.
31. Gorlero F, Macchiavalo S, Pellegatta L et al. Evaluation of the efficacy and tolerability of two different dosages of fenticonazole vaginal ovules (600 mg and 1000 mg) in patients with vaginal tricomoniasis: a controlled, double blind, randomized clinical trial versus placebo. Curr Ther Res 1994; 55: 510-518.
32. Gorlero F, Bosco P, Barbieri M et al. Fenticonazole ovules in the treatment of vaginal trichomonas infections. A double blind randomized pilot clinical trial. Curr Ther Res 1992; 51: 367-376.
33. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991; 29(2): 297-301.
34. Faro S. Tricomoniasis. In: Kaufman RH, Faro S, editors. Enfermedades benignas de la vulva y la vagina (Benign diseases of the vulva and vagina). Madrid: Mosby/Doyma Libres, S.A., 1996: 338-352.
35. Samuelson J. Why metronidazole is active against both bacteria and parasites. Antimicrob Agents Chemother 1999; 43(7): 1533-1541.
36. Forna F, Gulmezoglu AM. Interventions for treating trichomoniasis in women. Cochrane Database Syst Rev 2000;(3): CD000218.
37. Josephson S, Thomason J, Sturino K, Zabransky R, Williams J. Gardnerella vaginalis in the urinary tract: incidence and significance in a hospital population. Obstet Gynecol 1988; 71(2): 245-250.
38. Murta EF, Souza MA, Araujo JE, Adad SJ. Incidence of Gardnerella vaginalis, Candida sp and human papilloma virus in cytological smears. Sao Paulo Med J 2000; 118(4): 105-108.
39. Larsson PG. Treatment of bacterial vaginosis. Int J STD AIDS 1992; 3(4): 239-247.